FOLH1 and neoplasm: These bioconjugates effectively target cancer cells and trigger sustained intracellular drug release, leading to enhanced anti-tumor effects and reduced toxicity to non-target cells in vitro and in vivo compared to free drugs and drug-NP conjugates lacking PSMA aptamers [87-89].